### Check for updates

## OPEN ACCESS

EDITED AND REVIEWED BY Jian Zhong, Shanghai Jiao Tong University, China

\*CORRESPONDENCE

Gauthaman Kalamegam, gauthamank.sdc@saveetha.com Peter Natesan Pushparaj, peter.n.pushparaj@gmail.com

#### SPECIALTY SECTION

This article was submitted to Integrative and Regenerative Pharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 22 October 2022 ACCEPTED 09 November 2022 PUBLISHED 25 November 2022

#### CITATION

Pushparaj PN, Kalamegam G and Ramakrishna S (2022), Editorial: Methods and application in integrative and regenerative pharmacology: 2021. *Front. Pharmacol.* 13:1077352. doi: 10.3389/fphar.2022.1077352

### COPYRIGHT

© 2022 Pushparaj, Kalamegam and Ramakrishna. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic

practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: Methods and application in integrative and regenerative pharmacology: 2021

Peter Natesan Pushparaj<sup>1,2,3</sup>\*, Gauthaman Kalamegam<sup>3,4</sup>\* and Seeram Ramakrishna<sup>5</sup>

<sup>1</sup>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia, <sup>2</sup>Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, <sup>3</sup>Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India, <sup>4</sup>Pharmaceutical Division, Nibblen Life Sciences, Chennai, India, <sup>5</sup>Center for Nanofibers & Nanotechnology, Department of Mechanical Engineering, National University of Singapore, Singapore, Singapore

#### KEYWORDS

integrative and regenerative pharmacology, MiRNA-21, leptin, wound healing, intervertebral disc degeneration, biomaterials, stem cell therapy, pharmacotherapy

### Editorial on the Research Topic

Methods and application in integrative and regenerative pharmacology: 2021

## Introduction

The last decade has seen notable developments in the research environment of integrative and regenerative pharmacology (Richardson et al., 2016; Huwaikem et al., 2021; Irfan et al., 2022; Rani Raju, et al., 2022). Therefore, the Integrative and Regenerative Pharmacology special issue series aims to highlight the state-of-the-art experimental methods to explore fundamental issues and application of biomolecules in stem cell biology and the use of pharmacological agents in conjunction with biotechnological and nanotechnological principles. With our research theme, we aimed to attract manuscripts that focus on recent advances in basic and translational research and expand current knowledge of integrative and regenerative methods and their applications (https://www.frontiersin.org/research-topics/28076/methods-and-application-in-integrative-and-regenerative-pharmacology-2021). Fifteen manuscripts were submitted by authors from around the world. A of which were accented for publication after rigorous peer review. The

around the world, 4 of which were accepted for publication after rigorous peer review. The remaining 11 manuscripts were not accepted for publication. In this editorial article, we discuss the research articles and reviews published on our Research Topic, focusing on the role of microRNA (miR21)) and leptin in wound healing, research trends, and hotspots in

stem cell therapy for intervertebral disc degeneration (IDD) based on bibliometrics, and pharmacotherapy in experimental spinal cord injury (SCI) in rats.

# Role of miR21 and leptin in wound healing

In the Research Topic, Xie et al. reviewed the role of miR21 in wound healing. They reasoned that miR21 targets multiple biological processes and signaling pathways, especially the angiogenic and inflammatory pathways that are crucial in regulating the process of wound healing. More specifically, miR21 regulates intracellular signaling molecules such as programmed cell death protein 4 (PDCD4), phosphatase and tensin homolog (PTEN), reversion-inducing cysteine-rich protein with Kazal motifs (RECK), sprouty RTK signaling antagonist 1 (SPRY1), SPRY2, mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) and phosphatidylinositol 3 kinase/protein Kinase B (AKT) (PI3K/ AKT) (Xie and Weiskirchen, 2020) to either promote or delay the wound healing process. The authors emphasized that the progress in the development of miRNA nanocarrier systems might improve the clinical efficiency of such miRNA-based therapy. Although the effects of miR21 on wound healing have been preliminarily elucidated, the functions of miR21 in various types of wound healing need further investigation. Nevertheless, the comprehensive review by Xie et al. helps to underpin the fact that miR21 may serve as a potential therapeutic target for wound healing.

In the comprehensive review, Yuan et al. discussed the relationship between leptin, an anti-obesity hormone, and wound healing based on studies using both in vitro and in vivo models. Based on articles published in the field of wound healing, the authors state that regulation of inflammation by immune cells, re-epithelialization, proliferation, angiogenesis, and fibroblast differentiation are essential determinants in wound healing. The authors emphasized that the wound healing process promoted by leptin involves many signalling pathways, such as activation of signal transducer and activator of transcription 1 (STAT1) and STAT3 via p38 MAPK or janus kinase 2 (JAK2). Importantly, the authors discussed the delayed wound healing in leptindeficient mice and its reversal after leptin administration. However, the authors have rightly noted that although leptin promotes re-epithelialization and supports wound healing, the roles of leptin in the inflammation, proliferation, and maturation phases of wound healing are still nascent and require further research.

# Role of stem cells in intervertebral disc degeneration

Wang et al. applied systematic bibliometric and visual analysis methods to determine the role of stem cells (SCs) in intervertebral disc degeneration (IDD). The authors have comprehensively searched the Web of Science Core Collection (WOSCC), Scopus, PubMed, and ClinicalTrials.gov databases to collect the relevant literature for bibliometric and visual analysis. They used scientific software such as VOS viewer 1.6.17, CiteSpace 5.8.R.1, and Scimago Graphica for bibliometrics. Wang et al. found that most publications came from China and most international collaborations and citations came from the United States of America (USA). They identified the authors with the highest productivity and highest quality articles, the most frequently published and cited journals, and current hotspots such as mechanistic studies in SCs and IDD research. They also found studies supporting the use of tissueengineered scaffolds of SCs in degenerative disc disease. Importantly, they found that clinical trials were rare and direct injection of mesenchymal stem cells (MSCs) into degenerated discs for the treatment of degenerative disc disease (DDD) was the latest trend in this research area. In fact, direct injection of MSCs into degenerative discs have shortterm benefits which are mainly attributed to their paracrine effects rather than integration of SCs and tissue regeneration. As rightly mentioned in the article, there is a dearth of clinical trial studies and this needs to be stepped up to have more conclusive evidence to understand the role of SCs in IDD and other skeletal disorders.

## Pharmacotherapy for spinal cord injury

Hashemizadeh et al. demonstrated the benefits of early administration of bumetanide, a diuretic, in a rat model with spinal cord injury (SCI). The authors found that the chloride co-transporter Na + -K + - Cl- co-transporter isoform 1 (NKCC1) was upregulated in the center of the injured spinal cord 3 hours after lesion onset and peaked approximately 6 h after SCI. Treatment with bumetanide, an NKCC1 inhibitor, improved locomotor function and increased levels of the protein Growth Associated Protein-43 (GAP-43) 4 weeks after induction of SCI. The authors confirmed the beneficial effects of bumetanide through histologic tissue studies that exhibited neuroprotective and regenerative effects. Here, the authors provided new evidence for the beneficial effects of bumetanide when administered immediately after SCI.

02



Methods and Application in Integrative and Regenerative Pharmacology. Articles in the special issue (light red circles) address the role of miR21 and leptin in wound healing, stem cell therapy for intervertebral disc degeneration (IDD), and pharmacotherapy for experimental spinal cord injury (SCI) in rats. The future of integrative and regenerative pharmacology (light green circles) depends on research advances in the development and application of biomaterials, CRISPR-CAS9 Genome Editing, RNAi/RNAa rheostat, and next generation knowledge discovery methods and artificial intelligence (AI) tools (*Illustration created using BioRender*).

## Discussion

miRNAs are endogenous short RNA molecules consisting of 20–22 nucleotides (Pushparaj et al., 2008a; Pushparaj et al., 2008b). miRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of the target gene, promoting degradation or, in some cases, activation (Li et al., 2006; Li, 2017; Tan et al., 2021). miRNAs play an important role in the regulation of various biological processes such as cell differentiation, proliferation, apoptosis, cell migration, etc.

Thus, the dysregulation of miRNAs has been frequently observed in many pathologies, including wound healing and they have been proposed as therapeutic targets for several diseases.

Efficient wound healing is pivotal, and it is a chief burden for healthcare providers around the globe. Here, Xie et al. discussed the key role of miR21 in wound healing. However, based on some wound healing studies, the upregulation of miR21 decreased leptin levels in vascular ulcers (VUs) and the silencing of miR21 increased leptin levels (Pastar et al., 2012). On the other hand, similar to Xie et al. Yuan et al. pointed out that overexpression of miR21 enhanced wound healing in aged mice and that miR21 may play different roles depending on the type of wound (Long et al., 2018). Therefore, identifying and validating the biological mechanisms of miR21 and leptin in wound healing is essential for developing a therapy for wound healing.

Bibliometric studies are essential to deciphering global research trends and hotspots in a particular research area around the globe (Agarwal et al., 2021; Baskaran et al., 2021). The bibliometric study by Wang et al. revealed the global research hotspots, trends, and clinical use of SCs in the treatment of IDD. Bibliometrics helps researchers quickly grasp the hotspots and latest trends in research. Therefore, researchers can use the bibliometric methods as demonstrated by Wang et al. to decipher the necessary clues from the literature in the field of integrative and regenerative pharmacology to design and develop their research.

Disturbances of ionic balance are common in SCI because the activity of y-aminobutyric acid (GABA) receptors depends on intracellular chloride levels. Chloride homeostasis is controlled by two co-transporters, NKCC1 and K + -Clco-transporter (KCC2), which are essential for chloride homeostasis. NKCC1 has been found to be disrupted in SCI (Nasirinezhad et al., 2021). The axonal pathways that control sensory and motor functions are affected in SCI, leading to neuronal impairments (O'Shea et al., 2017). Hashemizadeh et al. discovered bumetanide, an inhibitor of NKCC1, in a rat model of SCI and noted the beneficial effects of this diuretic drug. Previously, bumetanide was found to have analgesic effects on neuropathic pain in patients with SCI (Zarepour et al., 2020). Therefore, the development of new or repurposed drugs in regenerative medicine is essential for better patient care in clinics.

Advances in the field of biomaterials for stem cell and drug delivery in the last decade have given a much-needed boost to the development of regenerative medicine (Sankar et al., 2017; Farokhi et al., 2021; Pishavar et al., 2021; Irfan et al., 2022; Maruthi and Ramakrishna, 2022). The research progress and development in the field of RNA interference (RNAi) and RNA activation (RNAa) (Li et al., 2006; Pushparaj et al., 2008a; Pushparaj et al., 2008b; Li, 2017; Tan et al., 2021), CRISPR-CAS9 gene editing methods, and the potential application of next-generation knowledge discovery platforms in basic and translational research (Pushparaj et al., 2022) in integrative and regenerative pharmacology are essential for the development of personalized therapies (Figure 1).

## Conclusion and future directions

Articles submitted under the Research Topic highlight the importance of miR21 and leptin signaling in wound healing,

the use of human umbilical cord mesenchymal stem cells (HUC-MSCs), BM -MSCs, and adipose-derived stem cells in IDD, and the benefits of bumetanide when administered early after SCI in an experimental animal model. In addition to stem cell-based therapy, CRISPR/cas9 genome editing strategies are the most recent advances that have contributed to the advancement of life sciences (Doudna and Charpentier, 2014). In the future, it is important to apply CRISPR/ cas9 genome editing in stem cells and test it using in vitro and in vivo disease models (Ohmori et al., 2017; Carlson-Stevermer and Saha, 2017; Saha et al., 2021; Nakano et al., 2022) to develop personalized therapy. However, advances in the development and application of biomaterials, nextgeneration knowledge discovery and artificial intelligence (AI) tools, RNAi/RNAa rheostat, novel drugs, and CRISPR-CAS9 genome editing methods will determine the success of translating research findings in integrative and regenerative pharmacology into the clinic.

## Author contributions

PP, GK, and SR: Idea for the Research Topic, preparation of the description of the Research Topic, and appointment of the review committee. PP and GK: Discussion of the Research Topic and its implementation. PP, GK, and SR: Selection of the review panel for each manuscript and decision on preliminary acceptance/rejection.

## Funding

The authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia, for funding this research work through the project number (1045).

## Acknowledgments

We would like to thank all the authors who contributed their cutting-edge research to this Research Topic. In addition, we would like to thank all the reviewers who dedicated their time and efforts to review the submitted manuscripts.

## Conflict of interest

GK was employed by the company Nibblen Life Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

## References

Agarwal, A., Panner Selvam, M. K., Baskaran, S., Finelli, R., Leisegang, K., Barbăroșie, C., et al. (2021). A scientometric analysis of research publications on male infertility and assisted reproductive technology. *Andrologia* 53 (1), e13842. doi:10.1111/and.13842

Baskaran, S., Agarwal, A., Leisegang, K., Pushparaj, P. N., Panner Selvam, M. K., and Henkel, R. (2021). An in-depth bibliometric analysis and current perspective on male infertility research. *World J. Mens. Health* 39 (2), 302–314. doi:10.5534/wjmh. 180114

Carlson-Stevermer, J., and Saha, K. (2017). Genome editing in human pluripotent stem cells. *Methods Mol. Biol.* 1590, 165–174. doi:10.1007/978-1-4939-6921-0\_12

Doudna, J. A., and Charpentier, E. (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Sci. (New York, N.Y.)* 346 (6213), 1258096. doi:10.1126/science.1258096

Farokhi, M., Mottaghitalab, F., Saeb, M. R., Shojaei, S., Zarrin, N. K., Thomas, S., et al. (2021). Conductive biomaterials as substrates for neural stem cells differentiation towards neuronal lineage cells. *Macromol. Biosci.* 21 (1), e2000123. doi:10.1002/mabi.202000123

Huwaikem, M., Kalamegam, G., Alrefaei, G., Ahmed, F., Kadam, R., Qadah, T., et al. (2021). Human wharton's jelly stem cell secretions inhibit human leukemic cell line K562 *in vitro* by inducing cell cycle arrest and apoptosis. *Front. Cell Dev. Biol.* 9, 614988. doi:10.3389/fcell.2021.614988

Irfan, D., Ahmad, I., Patra, I., Margiana, R., Rasulova, M. T., Sivaraman, R., et al. (2022). Stem cell-derived exosomes in bone healing: Focusing on their role in angiogenesis. *Cytotherapy* S1465-3249 (22)00781–00782. doi: doi:10.1016/j.jcyt. 2022.08.008

Li, L. C., Okino, S. T., Zhao, H., Pookot, D., Place, R. F., Urakami, S., et al. (2006). Small dsRNAs induce transcriptional activation in human cells. *Proc. Natl. Acad. Sci. U. S. A.* 103 (46), 17337–17342. doi:10.1073/pnas.0607015103

Li, L. C. (2017). Small RNA-guided transcriptional gene activation (RNAa) in mammalian cells. *Adv. Exp. Med. Biol.* 983, 1–20. doi:10.1007/978-981-10-4310-9\_1

Long, S., Zhao, N., Ge, L., Wang, G., Ran, X., Wang, J., et al. (2018). MiR-21 ameliorates age-associated skin wound healing defects in mice. *J. Gene Med.* 20 (6), e3022. doi:10.1002/jgm.3022

Maruthi, Y. A., and Ramakrishna, S. (2022). Sporopollenin - invincible biopolymer for sustainable biomedical applications. *Int. J. Biol. Macromol.* S0141-8130 (22), 2957–2965. doi:10.1016/j.ijbiomac.2022.10.071

Nakano, Y., Susa, K., Yanagi, T., Hiraoka, Y., Suzuki, T., Mori, T., et al. (2022). Generation of NPHP1 knockout human pluripotent stem cells by a practical biallelic gene deletion strategy using CRISPR/Cas9 and ssODN. *Vitro Cell. Dev. Biol. Anim.* 58 (2), 85–95. doi:10.1007/s11626-022-00655-0

Nasirinezhad, F., Zarepour, L., Hadjighassem, M., Gharaylou, Z., Majedi, H., and Ramezani, F. (2021). Analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury. *Basic Clin. Neurosci.* 12 (3), 409–420. doi:10.32598/bcn.12. 3.2049.1

O'Shea, T. M., Burda, J. E., and Sofroniew, M. V. (2017). Cell biology of spinal cord injury and repair. J. Clin. Invest. 127 (9), 3259–3270. doi:10.1172/JCI90608

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Ohmori, T., Nagao, Y., Mizukami, H., Sakata, A., Muramatsu, S. I., Ozawa, K., et al. (2017). CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. *Sci. Rep.* 7 (1), 4159. doi:10.1038/s41598-017-04625-5

Pastar, I., Khan, A. A., Stojadinovic, O., Lebrun, E. A., Medina, M. C., Brem, H., et al. (2012). Induction of specific microRNAs inhibits cutaneous wound healing. *J. Biol. Chem.* 287 (35), 29324–29335. doi:10.1074/jbc.M112.382135

Pishavar, E., Khosravi, F., Naserifar, M., Rezvani Ghomi, E., Luo, H., Zavan, B., et al. (2021). Multifunctional and self-healable intelligent hydrogels for cancer drug delivery and promoting tissue regeneration *in vivo. Polymers* 13 (16), 2680. doi:10. 3390/polym13162680

Pushparaj, P. N., Aarthi, J. J., Kumar, S. D., and Manikandan, J. (2008). RNAi and RNAa--the yin and yang of RNAome. *Bioinformation* 2 (6), 235–237. doi:10.6026/97320630002235

Pushparaj, P. N., Aarthi, J. J., Manikandan, J., and Kumar, S. D. (2008). siRNA, miRNA, and shRNA: *In vivo* applications. *J. Dent. Res.* 87 (11), 992–1003. doi:10. 1177/154405910808701109

Pushparaj, P. N., Kalamegam, G., Wali Sait, K. H., and Rasool, M. (2022). Decoding the role of astrocytes in the entorhinal cortex in alzheimer's disease using high-dimensional single-nucleus RNA sequencing data and next-generation knowledge discovery methodologies: Focus on drugs and natural product remedies for dementia. *Front. Pharmacol.* 12, 720170. doi:10.3389/fphar.2021. 720170

Rani Raju, N., Silina, E., Stupin, V., Manturova, N., Chidambaram, S. B., and Achar, R. R. (2022). Multifunctional and smart wound dressings-A review on recent research advancements in skin regenerative medicine. *Pharmaceutics* 14 (8), 1574. doi:10.3390/pharmaceutics14081574

Richardson, S. M., Kalamegam, G., Pushparaj, P. N., Matta, C., Memic, A., Khademhosseini, A., et al. (2016). Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration. *Methods (San Diego, Calif.)* 99, 69–80. doi:10.1016/j.ymeth.2015.09.015

Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., et al. (2021). The NIH somatic cell genome editing program. *Nature* 592 (7853), 195–204. doi:10.1038/s41586-021-03191-1

Sankar, S., Sharma, C. S., Rath, S. N., and Ramakrishna, S. (2017). Electrospun fibers for recruitment and differentiation of stem cells in regenerative medicine. *Biotechnol. J.* 12 (12), 1700263. doi:10.1002/biot.20170026310.1002/biot.201700263

Tan, C. P., Sinigaglia, L., Gomez, V., Nicholls, J., and Habib, N. A. (2021). RNA activation-A novel approach to therapeutically upregulate gene transcription. *Mol.* (*Basel, Switz.* 26 (21), 6530. doi:10.3390/molecules26216530

Xie, J., and Weiskirchen, R. (2020). What does the "AKT" stand for in the name "AKT kinase"? Some historical comments. *Front. Oncol.* 10, 1329. doi:10.3389/fonc. 2020.01329

Zarepour, L., Gharaylou, Z., Hadjighassem, M., Shafaghi, L., Majedi, H., Behzad, E., et al. (2020). Preliminary study of analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury. *J. Clin. Neurosci.* 81, 477–484. doi:10.1016/j. jocn.2020.10.010